Consider reaching out to healthcare professionals who specialize in EDS, as well as support groups and organizations like The Ehlers-Danlos Society, which can provide valuable resources and community support
Molecular Architecture Why Asymmetric Receptor Affinity is by Design Tirzepatide is not a balanced dual agonist in the strict pharmacological sense, its binding affinities at GIPR and GLP-1R differ by roughly an order of magnitude, and this imbalance is the result of deliberate engineering rather than synthetic limitation
Robelin L, Gonzalez De Aguilar JL
Targeted profiling of arachidonic acid and eicosanoids in rat tissue by UFLC-MS/MS: Application to identify potential markers for rheumatoid arthritis
The effects of severe renal impairment on the pharmacokinetics of edaravone have not been studied Hepatic impairment: No dosage adjustments are necessary in patients with hepatic impairment The multicenter clinical trial for RADICAVA ORS included male and female patients (aged 18-75) in the United States, Canada, France, Germany, Italy, and Japan, and included people of various ethnicities 5 RADICAVA ORS - the ONLY FDA-approved oral form of edaravone - was built on years of clinical research and development a Occurred in 10% of patients on RADICAVA and 2% more frequently than placebo
